Brain cancer vaccine - Advanced Biotherapies

Drug Profile

Brain cancer vaccine - Advanced Biotherapies

Alternative Names: Antisense TGF-beta-2 gene therapy

Latest Information Update: 01 Jun 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advanced Biotherapies
  • Class Antisense DNA; Cancer vaccines; Cell therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants; Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jun 2006 No development reported - Phase-I for Glioblastoma in USA (SC)
  • 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top